Sustainability | February 22, 2022
AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers
New inhalers would have near-zero Global Warming Potential propellant
New inhalers would have near-zero Global Warming Potential propellant
The sale is expected to close in the first quarter of 2022
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Subscribe To Our Newsletter & Stay Updated
